Allakos Inc. (ALLK) financial statements (2021 and earlier)

Company profile

Business Address 975 ISLAND DRIVE
REDWOOD CITY, CA 94065
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:659420455480496517153
Cash and cash equivalents2071041541363830936
Short-term investments452315301344458208117
Other undisclosed cash, cash equivalents, and short-term investments00(0)(0)(0)(0)0
Other undisclosed current assets10534431
Total current assets:669425458484500520154
Noncurrent Assets
Operating lease, right-of-use asset4066666 
Property, plant and equipment8788889
Restricted cash and investments      1
Other noncurrent assets2333311
Other undisclosed noncurrent assets      5
Total noncurrent assets:50161617171515
TOTAL ASSETS:720441474500517535170
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2219201413129
Accounts payable148109643
Accrued liabilities811105796
Total current liabilities:2219201413129
Noncurrent Liabilities
Long-term debt and lease obligation43      
Operating lease, liability43      
Liabilities, other than long-term debt 888888
Other liabilities 888888
Other undisclosed noncurrent liabilities(43)      
Total noncurrent liabilities: 888888
Total liabilities:65272722212118
Stockholders' equity
Stockholders' equity attributable to parent654414447478496514152
Common stock0000000
Additional paid in capital997712703693685679295
Accumulated other comprehensive income0012000
Accumulated deficit(343)(299)(257)(217)(189)(165)(143)
Total stockholders' equity:654414447478496514152
TOTAL LIABILITIES AND EQUITY:720441474500517535170

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(44)(42)(40)(30)(27)(24)(20)
Operating loss:(44)(42)(40)(30)(27)(24)(20)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)(0)(0)0(0)(0)0
Loss from continuing operations before equity method investments, income taxes:(45)(43)(41)(30)(27)(24)(20)
Other undisclosed income from continuing operations before income taxes    6  
Loss before gain (loss) on sale of properties:(45)(43)(41)(30)(21)(24)(20)
Other undisclosed net income (loss)0  2(4)  
Net loss:(44)(43)(41)(28)(25)(24)(20)
Other undisclosed net income attributable to parent 11  21
Net loss available to common stockholders, diluted:(44)(42)(39)(28)(25)(22)(19)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(44)(43)(41)(28)(25)(24)(20)
Comprehensive loss:(44)(43)(41)(28)(25)(24)(20)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)002021
Comprehensive loss, net of tax, attributable to parent:(44)(43)(41)(26)(25)(22)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: